Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ «Федеральный медицинский исследовательский центр психиатрии и наркологии им. В.П.Сербского» Минздрава России. 119992, Россия, Москва, Кропоткинский пер., д. 23
M.P.Marachev V.P.Serbsky Federal Medical Research Center of Psychiatry and Narcology of the Ministry of Health of the Russian Federation. 119992, Russian Federation, Moscow, Kropotkinsky per., d. 23
Список исп. литературыСкрыть список 1. Webster’s 1913 Dictionary, The Free DictionaryWebster N. Webster's Revised Unabridged Dictionary of the English Language: The Dictionary Proper Being the Authentic Ed. of Webster's International Dictionary of One Thousand Eight Hundred and Ninety, Ed. Under the Supervision of Noah Porter... to which is Now Added a Department of New Words, Together with Many Valuable Special Features. G. & C. Merriam Company, 1913; http://www.webster-dictionary.org/ 2. Frank E et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48 (9): 851–5. 3. Nierenberg AA et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60 (4): 221–5. 4. Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry 2003; 64 (Suppl. 13): 18–25. 5. Demyttenaere K, Andersen HF, Reines EH. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. Int Clin Psychopharmacol 2008; 23 (5): 276–86. 6. Thase ME, Sloan DM, Kornstein SG. Remission as the critical outcome of depression treatment. Psychopharmacol Bull 2001; 36 (4): 12–25. 7. Aberg-Wistedt A et al. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000; 20 (6): 645–52. 8. Demyttenaere K et al. Six-month compliance with antidepressant medication in the treatment of major depressive disorder. Int Clin Psychopharmacol 2008; 23 (1): 36–42. 9. Judd LL et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998; 50: 97–108. 10. Judd LL et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998; 55 (8): 694–700. 11. Zimmerman M et al. How should remission from depression be defined? The depressed patient’s perspective. Am J Psychiatry 2006; 163 (1): 148–150. 12. Demyttenaere K et al. What is important in being cured from: Does discordance between physicians and patients matter? (2). J Affect Disord 2015; 174: 372–7. 13. Uher R et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med 2012; 42 (5): 967–80. 14. Mintz J et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992; 49 (10): 761–8; 15. Ormel J et al. Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects. Arch Gen Psychiatry 2004; 61 (4): 387–92. 16. Waghorn GR, Chant DC, King R. Work-related subjective experiences, work-related self-efficacy, and career learning among people with psychiatric disabilities. Am J Psychiatric Rehabilitation 2007; 10 (4): 275–300. 17. Nelson JC et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004; 55 (3): 296–300. 18. Li N et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329 (5994): 959–64. 19. Millan MJ et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-HP2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306 (3): 954–64. 20. Chenu F, El Mansari M, Blier P. Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. Neuropsychopharmacology 2013; 38 (2): 275–84. 21. Molteni R et al. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry 2010; 11 (2): 148–53. 22. Soumier A et al. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 2009; 34 (11): 2390–403. 23. Racagni G, Popoli M. The pharmacological properties of antidepressants. Int Clin Psychopharmacol 2010; 25 (3): 117–31. 24. Mouchabac S et al. Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city. Encephale 2002; 29 (5): 438–44. 25. Miller IW et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clini Psychiatry 1998; 59 (11): 608–19. 26. Taylor D, et al. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014; 348: g1888. 27. Khoo AL et al. Network meta-analysis and cost-effectiveness analysis of new generation antidepressants. CNS drugs 2015; 29 (8): 695–712. 28. Kennedy SH et al. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Eur Neuropsychopharmacol 2016; 26 (2): 378–89. 29. Gourion D, Mouchabac S. Étude prospective des relations entre anhédonie et fonctionnement social dans une large cohorte de patients traités pour épisode dépressif majeur par des médecins généralistes. Eur Psychiatry 2015; 30 (8): S147–S148. 30. Llorca PM, Gourion D. Course of anhedonia and depressive symptoms in a population of depressed outpatients treated with agomelatine. Eur Neuropsychopharmacol 2014; 24 (Suppl. 2): S468. 31. Gorwood P et al. Psychomotor retardation is a scar of past depressive episodes, revealed by simple cognitive tests. Eur Neuropsychopharmacol 2014; 24 (10): 1630–40.